You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The collaboration will allow the companies to expand pralsetinib to multiple cancer indications and explore codevelopment of a next-generation RET inhibitor.
The Cambridge, Massachusetts-based company recently reported positive interim results for the RET-targeting agent from the Phase I/II ARROW study.
Given the rarity of NTRK fusions, the company is also rolling out a free testing program to identify NTRK fusion-positive patients who would benefit from treatment.
NeoGenomics will offer the Thyroid Profile and the NGS Thyroid Profile plus RET FISH test as part of the program, which is sponsored by Lilly.
An analysis of pediatric cancer survivors suggests subsequent neoplasm risk can increase after certain genotoxic treatments in those with DNA repair gene changes.
At ASCO, Blueprint presented positive data on its RET inhibitor pralsetinib across a range of cancers and in a call with investors discussed regulatory plans in lung and thyroid cancers.
The accelerated approval was granted based on data submitted from the Phase I/II LIBRETTO-001 trial.
The firms will evaluate Stratafide, a pan-solid tumor diagnostic test designed to identify actionable genomic alterations in tissue or blood samples.
The company announced that it is planning to submit an NDA for the drug in RET-mutant medullary thyroid cancer.
The randomized, 400-patient trial will compare selpercatinib to chemotherapy for first-line treatment of medullary thyroid cancer.